Sort   by:  
 Page size 
UnknownThe National Lung Screening Trial: overview and study design.
Not available
S-EPMC3009383 | biostudies-literature
UnknownSafety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Not available
S-EPMC8639161 | biostudies-literature
UnknownSafety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Not available
S-EPMC9084623 | biostudies-literature
UnknownMetformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial.
Not available
S-EPMC12261116 | biostudies-literature
UnknownTime to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.
Not available
S-EPMC11581631 | biostudies-literature
UnknownHigher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
Not available
S-EPMC10656670 | biostudies-literature
UnknownEffect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.
Not available
S-EPMC10064277 | biostudies-literature
UnknownViral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.
Not available
S-EPMC2745911 | biostudies-literature
UnknownFactors associated with D-dimer levels in HIV-infected individuals.
Not available
S-EPMC3953205 | biostudies-literature
UnknownResults of the two incidence screenings in the National Lung Screening Trial.
Not available
S-EPMC4307922 | biostudies-literature
Sort   by:  
 Page size